DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for mesenchymal chondrosarcoma — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMesenchymal chondrosarcoma maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mesenchymal chondrosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
androgen receptor (AR) — AR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1r,2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5CJ6 · 2.07 Å · ligand 2-chloro-4-{[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino}-3-methylbenzonitrile (51Y). Experimental structure, not a prediction.
What the evidence adds up to
Mesenchymal chondrosarcoma is a rare, aggressive neoplasm. The mesenchymal subtype carries a poor prognosis. In approximately 50% of patients with extraskeletal mesenchymal chondrosarcoma, a soft tissue lesion and stippled calcification can be seen on conventional radiography. One case report describes a 47-year-old man with a painless, mobile, nontender, firm mass in the left shoulder, treated with wide resection followed by radiation therapy. Another case report describes a mesenchymal chondrosarcoma of the mandible, noting that mandibular involvement is exceptional.
The literature reviewed in these case reports is limited to single-patient experiences. The 2016 report states that complete wide resection may be enough as initial treatment and that chemotherapy is reserved for patients with unresectable masses. The 2022 report reviews epidemiological, diagnostic, and therapeutic aspects but provides no new treatment data or outcomes. No drug therapy is mentioned in any of the abstracts.
No controlled trials, no survival statistics, no response rates, and no drug interventions are reported for mesenchymal chondrosarcoma in these abstracts. What is missing is any prospective trial design, any patient stratification, and any funding for systematic investigation of systemic therapies for this rare sarcoma.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2016 · 3 citations · open access
Extraskeletal Mesenchymal Chondrosarcoma of Shoulder: An Extremely Rare Case.
AbstractINTRODUCTION: Extraskeletal chondrosarcoma (EMC) is a rare, aggressive neoplasm which has been seen in the soft tissue area. This soft tissue sarcoma is classified to myxoid and mesenchymal based on histologic criteria. The mesenchymal subtype has a poor prognosis. In approximately 50% of patient with EMC, we could observe soft tissue lesion and stippled calcification in the conventional radiography. CASE REPORT: In the current paper, we introduced a 47-year-old Iranian male patient having painless, mobile, nontender, and firm mass in left shoulder. We did not find neurovascular disturbance at the upper extremity, and the patient had a full range of motion in the left shoulder. The tumor was treated with wide resection and followed by radiation therapy. CONCLUSION: Complete wide resection of mesenchymal chondrosarcoma could be enough as an initial treatment and chemotherapy reserved for patients that have unresectable masses. Apparently, the main key in the treatment is the surgical resection, and this process is the most important method in their management.
International Journal of Current Science Research and Review · 2022 · 1 citations · open access
A Case Report of a Mesenchymal Chondrosarcoma of the Mandible
AbstractMesenchymal chondrosarcoma is a rare variety of chondrosarcoma. The localization in the head and neck is rare and mandibular involvement is exceptional. It is characterized by the formation of cartilage by the tumor cells. We report a rare case of a mesenchymal chondrosarcoma of the mandible, through this case, and in the light of the literature we will review the epidemiological, diagnostic and therapeutic aspects of this rare malignant tumor.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
A Case Report of a Mesenchymal Chondrosarcoma of the Mandible
AbstractAbstract : Mesenchymal chondrosarcoma is a rare variety of chondrosarcoma. The localization in the head and neck is rare and mandibular involvement is exceptional. It is characterized by the formation of cartilage by the tumor cells. We report a rare case of a mesenchymal chondrosarcoma of the mandible, through this case, and in the light of the literature we will review the epidemiological, diagnostic and therapeutic aspects of this rare malignant tumor.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
